Table 1.
Clinical variables in 124 patients with COVID-19.
| Variable | Normal range | Non-severe (n = 87) |
Severe (n = 25) |
Critical (n = 12) |
Total (n = 124) |
Total increased |
Total decreased |
|
|---|---|---|---|---|---|---|---|---|
| mean ± SD (range) | No. (%) | |||||||
| PLT (109/L) | 125–350 | 193.5 ± 70.5 (83–396) | 187.6 ± 100.0 (54–525) | 187.3 ± 103.7 (85–442) | 191.7 ± 80.0 (54–525) | 3 (2.4%) | 25 (20.2%) | |
| Lymphocyte (109/L) | 1.1–3.2 | 1.1 ± 0.3 (0.1–5.0) | 0.8 ± 0.3∗ (0.3–1.7) | 0.6 ± 0.4∗ (0.3–1.4) | 0.9 ± 0.6 (0.1–5.0) | – | – | |
| —Decrease no. (%) | – | 57 (65.5%) | 22 (88.0%) | 10 (83.3%) | – | 2 (1.6%) | 89 (71.8%) | |
| MPV (fL) | 6–12 | 9.1 ± 1.2 (6.6–11.9) | 9.1 ± 1.5 (7.3–12.3) | 9.4 ± 1.7 (6.6–11.2) | 9.1 ± 1.3 (6.6–12.3) | 1 (0.8%) | 0 | |
| PT (S) | 9.4–12.5 | 12.9 ± 1.4 (8.6–17.8) | 13.0 ± 1.5 (11.1–17.6) | 13.3 ± 1.6 (11.4–15.8) | 13.0 ± 1.4 (8.6–17.8) | 77 (62.1%) | 1 (0.8%) | |
| APTT (S) | 25.1–36.5 | 30.4 ± 3.1 (22.9–38.1) | 30.4 ± 2.5 (26.6–34.8) | 29.3 ± 4.5 (22.4–35.3) | 30.3 ± 3.2 (22.4–38.1) | 2 (1.6%) | 9 (7.3%) | |
| FIB (mg/dL) | 238–498 | 430.2 ± 80.3 (256–717) | 428.9 ± 91.0 (214–582) | 428.8 ± 139.4 (203–750) | 429.8 ± 88.7 (203–750) | 27 (21.8%) | 2 (1.6%) | |
| D-dimer (μg/L) | 0–500 | 746.5 ± 2279.7 (59–18825) | 1178.4 ± 4267.5 (35–21611) | 4138.3 ± 7506.7∗ (82–26315) | 1168.6 ± 3652.7 (35–26315) | – | – | |
| —Increase no. (%) | – | 15 (17.2%) | 4 (16.0%) | 7 (58.3%) | – | 26 (21.0%) | – | |
| CRP (mg/L) | 0–10 | 37.0 ± 43.4 (0.4–173.7) | 61.5 ± 63.8∗ (0.7–290.1) | 75.0 ± 59.4∗ (11.6–203.7) | 46.0 ± 51.4 (0.4–290.1) | 80 (64.5%) | – | |
| PCT (ng/mL) | <0.05 | 0.2 ± 0.2 (<0.05–0.65) | 0.3 ± 0.3 (<0.05–0.94) | 0.2 ± 0.2 (0.07–0.52) | 0.2 ± 0.2 (<0.05–0.94) | 38 (30.6%) | – | |
| IL-6 (pg/mL) | 0–7 | 39.3 ± 71.1 (2.03–522.2) | 55.6 ± 44.4 (2.64–180.5) | 81.4 ± 65.6∗ (7.69–204.3) | 48.3 ± 66.5 (2.03–522.2) | 79 (63.7%) | – | |
∗ P < 0.05 when compared to the non-severe group. –Not applicable.